AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06248229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing will begin the morning following Visit 2. Subjects in the placebo group will begin the study on 5 mg of placebo. Subjects will be advised to take one tablet each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment.
Study NCT05324878 — intervention group
Intervention type: OTHER
Intervention: Training
Description: Social workers/nurses participants are agreeing to participating in the training program (3 sessions of 2 hours over a period of six weeks - one session every 2 weeks), follow up training sessions (occurring monthly), mentorship calls with social worker faculty on the project team, recording one conversation between social worker and a patient for quality improvement purposes, and completing evaluation of the project interventions (5-minute questionnaire after each education session, 15-minute questionnaire at end of participation in project).
Study NCT04803409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splenic Ultrasound
Description: Splenic Ultrasound: Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care
Study NCT05570838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Functional Electrical Stimulation consist on applying a current on the damaged muscles when the patient is doing a task that requires them. 120 repetitions will be made on the 6 first sessions and 180 repetitions will be done after the sixth session
Study NCT05570838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Robotic-Assisted Therapy
Description: The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
Study NCT05570838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Robotic-Assisted Therapy
Description: The hand Robotic-Assisted Therapy will be applyed using the AMADEO robot for hand rehabilitation by Tyromotion. The protocol that will be used consists on 200 repetitions on the active-assisted mode with flexion and extension of all the finguers and 50 repetitions on the active mode.
Study NCT05962606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AON-D21
Description: AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Study NCT06368115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Educational materials on inappropriate prescribing and deprescribing.
Study NCT05962606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.
Study NCT05106283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep block and Combined Block
Description: Deep serratus anterior block and combined deep and superficial serratus anterior plane block will be applied to the patients under real-time ultrasound guidance.
Study NCT06184932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAHE
Description: Participants will self-initiate rehabilitative activities through the HAHE program.
Study NCT06184932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Participants will self-initiate rehabilitative activities through the Exergame program.
Study NCT05232396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-6R Monoclonal Antibody Injection 4mg/kg
Description: IL-6R Monoclonal Antibody Injection 4mg/kg i.v.,single use
Study NCT05232396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-6R Monoclonal Antibody Injection 6mg/kg
Description: IL-6R Monoclonal Antibody Injection 6mg/kg i.v. , single use
Study NCT05232396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-6R Monoclonal Antibody Injection 8mg/kg
Description: IL-6R Monoclonal Antibody Injection 8mg/kg i.v. , single use
Study NCT05232396 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Injection 8mg/kg
Description: Tocilizumab Injection 8mg/kg i.v., single use
Study NCT06360133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVN001 Ophthalmic Solution, 5%
Description: VVN001 Ophthalmic Solution, 5%
Study NCT06360133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VVN001 Ophthalmic Solution, Vehicle
Description: VVN001 Ophthalmic Solution, Vehicle
Study NCT06292689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardunolizumab
Description: 1. Not systematically treated:~   Cardunolizumab (10mg/kg) + Cisplatinum (50mg/m2)/ Carboplatinum (AUC 4-5) + Paclitaxel (175mg/m2) ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.~2. Previous systematic treatment:~Cardunolizumab (10mg/kg) + Chemotherapy regimen selected by the investigator ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.
Study NCT05598359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TA-65
Description: TA-65 is a purified small molecule extracted from Astragalus root
Study NCT05598359 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive formulation
Study NCT04713670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (A) T-V14
Description: vonoprazan(vocinti)-based triple therapy for 14 days (T-V14)
Study NCT04713670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (B) T-V7
Description: vonoprazan(vocinti)-based triple therapy for 7 days (T-V7)
Study NCT04713670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (C) D-V14
Description: vonoprazan(vocinti)-based dual therapy for 14 days (D-V14)
Study NCT04713670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (D) HD-V14
Description: vonoprazan(vocinti)-based high dose dual therapy for 14 days (HD-V14)
Study NCT04713670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (E) BQ-V14
Description: vonoprazan(vocinti)-based bismuth quadruple therapy for 14 days (BQ-V14)
Study NCT04713670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (F) RH-V14
Description: vonoprazan(vocinti)-based reverse hybrid therapy for 14 days (RH-V14)
Study NCT04713670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (G) BQ-L14
Description: lansoprazole(takepron)-based bismuth quadruple therapy for 14 days (BQ-L14)
Study NCT04713670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (H) T-L14
Description: lansoprazole(takepron)-based triple therapy for 14 days (T-L14)
Study NCT04872478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRX-2843
Description: MRX-2843 capsules
Study NCT05881928 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Valproate 500 Mg Prolonged-Release Oral Tablet
Description: sodium valproate tablet30 mg / kg / day , maximum 1500mg / day . LTG :
Study NCT05881928 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Description: lamotrigine tablet 0.5 mg/kg for 2 weeks in two divided doses , increased in 0.5mg/kg/day increments every 2weeks .
Study NCT05881928 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: E.E.G
Description: device recording of brain activity. During this painless test, small sensors are attached to the scalp to pick up the electrical signals produced by the brain. These signals are recorded by a machine and are looked at by a doctoris
Study NCT04754022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Transfusion Strategy
Description: Patients will receive a RBC transfusion if their Hb concentration is \<75 g/L (\<7.5 g/dL; \<4.7mmol/L) intraoperatively and/or postoperatively.
Study NCT04754022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal transfusion strategy
Description: Patients will receive a RBC transfusion if their Hb concentration is \<95 g/L (\<9.5 g/dL; \<5.9mmol/L) intraoperatively, or postoperatively in the ICU; and/or \<85 g/L (\< 8.5 g/dL; \<5.3mmol/L) on the ward.
Study NCT06477588 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Navigation
Description: Participants meet with Health Navigator twice in-person and receive 7 check-ins from the Health Navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services
Study NCT06477588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Navigation, Employment Navigation plus Contingency Management Intervention
Description: Participants meet with health navigator twice in-person and receive 7 check-ins from the health navigator over a 6 month period. The health navigator provides participants with referrals and support to HIV, mental health, substance use, and other supportive services. Participants meeting with the employment navigator twice in-person and receive 10 check-ins from the employment navigator over 12 months. The employment navigator provides participants with referrals to employment and career development opportunities in the community and up to $200 for employment and career development support (e.g., transportation to interview, GED preparation course). Participants also receive up to $140 for HIV/STI care, treatment, and prevention milestones as part of the contingency management interview over a period of 12 months.
Study NCT06058585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: Finerenone 10mg or 20mg tablets, oral, once daily
Study NCT06058585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Finerenone
Description: Finerenone matched placebo tablets, oral, once daily
Study NCT06197217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01
Description: Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
Study NCT06197217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
Study NCT04774315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: omalizumab 300mg SQ every 4 weeks as part of standard of care
Study NCT04889079 — intervention group
Intervention type: BEHAVIORAL
Intervention: Contraceptive use (continuation/switching/discontinuation)
Description: Assessing contraceptive continuation/switching/discontinuation over 12-months
Study NCT05650905 — intervention group
Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer (DVA)
Description: Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA
Study NCT05650905 — intervention group
Intervention type: DEVICE
Intervention: Fourier domain optical coherence tomography (FDOCT)
Description: Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT
Study NCT05650905 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography (OCT)
Description: Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT
Study NCT05650905 — intervention group
Intervention type: DEVICE
Intervention: Laser Speckle Flowgraphy (LSFG)
Description: Normalized blur and Relative flow volume will be assessed using the LSFG
Study NCT05650905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics and Metabolites in Plasma, tear fluid and finger sweat
Description: Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test
Study NCT05315024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluarix Tetra
Description: Fluarix Tetra
Study NCT05315024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod cream
Description: Imiquimod cream
Study NCT06177015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide continuous
Description: standard of care
Study NCT06177015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide intermittent
Description: experimental group
Study NCT05648123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
Study NCT05648123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy
Description: Supportive psychotherapy is a treatment that uses direct measures to ameliorate symptoms and to maintain, restore or improve self-esteem, ego function, and adaptive skills
Study NCT05187494 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional local palatine injection
Description: Conventional palatal injection with anesthetic (lidocaine HCL2% with Epinephrine 1:80000, Korea) Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
Study NCT05187494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream only
Description: Emla cream will be applied at a distance of 1 mm from the palatine gingival edge by cotton buds for 3 minutes within the application area 14\*14 mm and the mouth will be open throughout the procedure and the saliva will be controlled by a saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
Study NCT05187494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemical permeability enhancer DMSO with EMLA cream
Description: Adding 10 g of EMLA cream 5%, 1,026 g of DMSO 100% and it will be applied with cotton bud for a period of 3 minutes while the child is opening his mouth and the saliva is controlled by saliva absorbent. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
Study NCT05187494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral patches with EMLA Cream
Description: EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an oral patch 14\*14 mm for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness
Study NCT05187494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro-needle patches dissolved with EMLA Cream
Description: EMLA cream 5% will be applied at a distance of 1 mm from the palatal gingival edge using an micro-needle patch 14\*14 mm, 0,25 micron for 3 minutes and the Mouth will be closed throughout the procedure. Then the palatal probe will be performed with a dental probe in contact with the bone to estimate anesthetic effectiveness.
Study NCT05166486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenic exercise
Description: Exercises involving major muscle groups will be given. Before starting the calisthenic exercises, they will be asked to perform 10 repetitive warm-ups and breathing exercises. The intensity of the calisthenic exercises will be adjusted on a weekly basis.~Calisthenic exercises are repeated 10-15 times in the first and second weeks; third and fourth weeks 15-20 repetitive; In the five, six, seven and eight weeks, it will be done with 25-30 repetitions.~Patients will be asked to keep an exercise diary and weekly follow-ups will be made over the phone.~Within eight weeks, each patient will come for control twice a month and will be asked to perform the exercises individually under the supervision of a physiotherapist. Patients will be asked to do the exercises three times a week for 8 weeks.
Study NCT06049251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELDOA exercises
Description: The patients will be asked to sit down on a floor in upright position and keep their legs apart and knees semi-flexed, feet in outward and upward position, knees constantly pushing downwards, straight lower back, raise arms with palms facing upward, and chin should be pulled back.~ELDOA stretch for L5-S1 level Patients will be asked to lay on floor and flatten and bring their legs up and straight with the support of wall, straight knees and keep distance between them, connect their toes, raise arm and externally rotate with wrist extension than press their heels and palms out.~ELDOA exercises will be performed with 2 sets of 5 repetitions with 45 second hold and15 sec rest between each set once a day.
Study NCT06049251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar SNAGS and motor control exercises
Description: The patient will be seated and his pelvis will be stabilized with belt at the level of the anterior superior iliac spine while the SNAGs are administered. The ulnar aspect of the therapist's hand will be placed over the spinous processes of the affected segment's superior vertebrae, for flexion glide and inferior vertebrae for extension glide respectively. A passive glide will be applied and kept up until the patient finished a full movement arc. The glides will be given for six repetitions for three sets every session. Glide can be given unilateral for other movements.~Motor Control Exercises:~Exercise training with 7sec Hold and 10 reps
Study NCT06296966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSJ-110
Description: ophthalmic solution
Study NCT06296966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ophthalmic solution
Study NCT05658978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: Neuromuscular training Length: 12 weeks; Training duration: 90 minutes; Intensity: 70-95%; 3 days per week. The intensity of the training is increasing in the first 20 minutes, and the intensity is gradually decreasing in the next 5 minutes; Rest: 30 seconds rest between exercises and 1-minute rest between sets.
Study NCT05658978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The Control group continues previous regular exercises for 12 weeks with a duration of 90 minutes and three days per week.
Study NCT05545358 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Short-Form McGill Pain Questionnaire (SF-MPQ) Pain Disability Index (PDI) Prosthesis Evaluation Questionnaire (PEQ) Psychological Inflexibility to Pain Scale (PIPS) Chronic Pain Acceptance Questionnaire (CPAQ) Cognitive Difficulties Scale (CDS) Amputee Body Image Scale (ABIS) Trinity Amputation and Prosthesis Experience Scales (TAPES) Pain Catastrophizing Scale (PCS) Hospital Anxiety and Depression Scale (HAD) Credibility/Expectancy Questionnaire (CEQ) Short-Form Edinburgh Handedness Inventory (SF-EHI) Patient's Global Impression of Change (PGIC)
Study NCT05545358 — intervention group
Intervention type: DEVICE
Intervention: Brain and Spinal Cord functional Magnetic Resonance Imaging
Description: Brain and Spinal Cord functional Magnetic Resonance Imaging
Study NCT05545358 — intervention group
Intervention type: OTHER
Intervention: Proprioceptive training
Description: Proprioceptive muscular training via a mechanical vibration of low amplitude and frequency between 60 and 80 Hz applied to the tendons.
Study NCT05522985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triprilimab combined with TP
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Study NCT05522985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprilimab combined with TP
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Study NCT06349655 — intervention group
Intervention type: DRUG
Intervention: Azvudine
Description: Antiviral drug
Study NCT06349655 — intervention group
Intervention type: DRUG
Intervention: Paxlovid
Description: Antiviral drug
Study NCT05837533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication model
Description: During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
Study NCT05983185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prism adaptation therapy
Description: The investigators' research and clinical group is the US leader in implementing this intervention for spatial neglect and have brought it to more than 50 clinical centers, hospitals, and treatment organizations.
Study NCT05114967 — intervention group
Intervention type: OTHER
Intervention: mPAS questionnaire
Description: The modified Preoperative Anxiety Scale (mPAS) questionnaire as given in the article by Viola et al will be used after permission from the authors